Differences in the neurochemical and behavioural profiles of lisdexamfetamine methylphenidate and modafinil revealed by simultaneous dual-probe microdialysis and locomotor activity measurements in freely-moving rats

Journal of Psychopharmacology

Volumn 28, Issue 3, 2014, Pages 254-269

  Rowley, Helen L ^a   Kulkarni, Rajiv S ^a   Gosden, Jane ^a   Brammer, Richard J ^a   Hackett, David ^b   Heal, David J ^a  

^a RenaSci Ltd   (United Kingdom)

^b Shire Pharmaceuticals   (United Kingdom)

Author keywords

5 hydroxytryptamine; Dopamine; lisdexamfetamine; locomotor activity; methylphenidate; microdialysis; modafinil; noradrenaline; prefrontal cortex; striatum

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 5 HYDROXYINDOLEACETIC ACID; DOPAMINE; HOMOVANILLIC ACID; LISDEXAMFETAMINE; METHYLPHENIDATE; MODAFINIL; NORADRENALIN; SEROTONIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEHAVIOR; BRAIN LEVEL; CATECHOLAMINERGIC SYSTEM; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE UPTAKE; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DUAL PROBE MICRODIALYSIS; EXTRACELLULAR SPACE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LOCOMOTION; MALE; MICRODIALYSIS; NEUROCHEMISTRY; NEUROTRANSMISSION; NONHUMAN; NORADRENALIN RELEASE; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; SEROTONIN UPTAKE;

5-HYDROXYTRYPTAMINE; DOPAMINE; LISDEXAMFETAMINE; LOCOMOTOR ACTIVITY; METHYLPHENIDATE; MICRODIALYSIS; MODAFINIL; NORADRENALINE; PREFRONTAL CORTEX; STRIATUM;

ANIMALS; BEHAVIOR, ANIMAL; BENZHYDRYL COMPOUNDS; CENTRAL NERVOUS SYSTEM STIMULANTS; DEXTROAMPHETAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; METHYLPHENIDATE; MICRODIALYSIS; MOTOR ACTIVITY; PREFRONTAL CORTEX; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84895545578     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881113513850     Document Type: Article

References (51)

1. Andersen PH. The dopamine uptake inhibitor GBR 12909: Selectivity and molecular mechanism of action. Eur J Pharmacol. 1989 ; 166: 493-504
2. Arnsten AF, Dudley AG. Methylphenidate improves prefrontal cortical cognitive function through α2-adrenoceptor and dopamine D1 receptor actions: Relevance to therapeutic effects in Attention Deficit Hyperactivity Disorder. Behav Brain Funct. 2005 ; 1: 2
3. Barkley RA, DuPaul GJ, McMurray MB. Attention deficit disorder with and without hyperactivity: Clinical response to three dose levels of methylphenidate. Pediatrics. 1991 ; 87: 519-531
4. Baumann MH, Clark RD, Woolverton WL, et al. In vivo effects of amphetamine analogs reveal evidence for serotonergic inhibition of mesolimbic dopamine transmission in the rat. J Pharmacol Exp Ther. 2011a ; 337: 218-225
5. Baumann MH, Williams Z, Zolkowska D, et al. Serotonin (5-HT) precursor loading with 5-hydroxy-l-tryptophan (5-HTP) reduces locomotor activation produced by (+)-amphetamine in the rat. Drug Alcohol Depend. 2011b ; 114: 147-152
6. Berridge CW, Devilbiss DM, Andrzejewski ME, et al. Methylphenidate preferentially increase catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function. Biol Psychiatr. 2006 ; 60: 1111-1120
7. Biederman J, Swanson JM, Wigal SB, et al. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: Results of a randomized, double-blind, placebo-controlled, flexible-dose study. Pediatrics. 2005 ; 116: e777 - e784
8. Bradberry CW, Barrett-Larimore RL, Jatlow P, et al. Impact of self-administered cocaine and cocaine cues on extracellular dopamine in mesolimbic and sensorimotor striatum in rhesus monkeys. J Neurosci. 2000 ; 20: 3874-3883
9. Caldwell GW, Masucci JA, Yan Z, et al. Allometric scaling of pharmacokinetic parameters in drug discovery: Can human CL, Vss and t1/2 be predicted from in-vivo rat data?. Eur J Drug Metab Pharmacokinet. 2004 ; 29: 133-143
10. Cervo L, Romandini S, Samanin R. Evidence of serotonin-dopamine involvement in the inhibition of d-amphetamine stereotypy and appearance of stereotyped movements found respectively after acute and long-term treatment with morphine and methadone in rats. Life Sci. 1981 ; 29: 2585-2591
11. Cheetham SC, Prow MR, Dykes SG, et al. Differences in presynaptic mechanisms of the ADHD drugs, d-amfetamine and methylphenidate, revealed by 'neurochemical fingerprinting': Correlations between dopamine neurochemistry and behavioural function. Soc Neurosci Abst. 2010 ; 669: 21
12. De Saint Hilaire Z, Orosco M, Rouch C, et al. Variations in extracellular monoamines in the prefrontal cortex and medial hypothalamus after modafinil administration: A microdialysis study in rats. Neuroreport. 2001 ; 12: 3533-3537
13. Drevets WC, Gautier C, Price JC, et al. Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria. Soc Biol Psychiatry. 2001 ; 49: 81-96
14. Ferraro L, Tanganelli S, O'Connor WT, et al. The vigilance promoting drug modafinil increases dopamine release in the rat nucleus accumbens via the involvement of a local GABAergic mechanism. Eur J Pharmacol. 1996 ; 306: 33-39
15. Gatley SJ, Pan D, Chen R, et al. Affinities of methylphenidate derivatives for dopamine, norepinephrine and serotonin transporters. Life Sci. 1996 ; 58: 231-239
16. Greenhill LL, Biederman J, Boellner SW, et al. A randomized, double-blind, placebo-controlled study of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiat. 2006 ; 45: 503-511
17. HealDJ (2008) A method for identifying a compound for treating a disorder or condition associated with dysfunction of monoamine neurotransmission. UK Patent Office, Application GB 2447 949. Available at: http://www.google.co.uk/ url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&ved= 0CEcQFjAA&url=http%3A%2F%2Fextwww.patent.gov.uk%2Fp-find-publication-getPDF. pdf%3FPatentNo%3DGB2447949%26DocType%3DB%26JournalNumber%3D6306&ei= JfyEUpWJF5KrhAeE5oDIDA&usg=AFQjCNHvp8rEGH84fMjLB5-AQgKqVMvDGQ&bvm=bv. 56343320,d.ZG4
18. Heal DJ, Pierce DM. Methylphenidate and its isomers: Their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system. CNS Drugs. 2006 ; 20: 713-738
19. Heal DJ, Cheetham SC, Smith SL. The neuropharmacology of ADHD drugs in vivo: Insights on efficacy and safety. Neuropharmacol. 2009 ; 57: 608-618
20. Heal DJ, Buckley NW, Gosden J, et al. A preclinical evaluation of the discriminative and reinforcing properties of lisdexamfetamine in comparison to d-amfetamine, methylphenidate and modafinil. Neuropharmacology. 2013b ; 73: 348-58
21. Heal DJ, Smith SL, Findling RL. ADHD: Current and future therapeutics. Curr Top Behav Neurosci. 2012 ; 9: 361-390
22. Heal DJ, Smith SL, Gosden J, et al. Amfetamine, past and present - A pharmacological and clinical perspective. J Psychopharmacol. 2013a ; 27: 479-496
23. Hurd YL, Ungerstedt U. Ca2+ dependence of the amphetamine, nomifensine, and Lu 19-005 effect on in vivo dopamine transmission. Eur J Pharmacol. 1989 ; 166: 261-269
24. Ishizuka T, Murakami M, Yamatodani A. Involvement of central histaminergic systems in modafinil-induced but not methylphenidate-induced increases in locomotor activity in rats. Eur J Pharmacol. 2008 ; 578: 209-215
25. Jasinski DR. An evaluation of the abuse potential of modafinil using methylphenidate as a reference. J Psychopharmacol. 2000 ; 14: 53-60
26. Kuczenski R, Segal D. Concomitant characterization of behavioral and striatal neurotransmitter response to amphetamine using in vivo microdialysis. J Neurosci. 1989 ; 9: 2015-2065
27. Kuczenski R, Segal DS. Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: Comparison with amphetamine. J Neurochem. 1997 ; 68: 2032-2037
28. Laruelle M, Abi-Dargham A, van Dyck CH, et al. SPECT imaging of striatal dopamine release after amphetamine challenge. J Nucl Med. 1995 ; 36: 1182-1190
29. Madras BK, Xie Z, Lin Z, et al. Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro. J Pharmacol Exp Ther. 2006 ; 319: 561-569
30. Mantle TJ, Tipton KF, Garrett NJ. Inhibition of monoamine oxidase by amphetamine and related compounds. Biochem Pharmacol. 1976 ; 25: 2073-2077
31. Martinez D, Narendran R, Foltin RW, et al. Amphetamine-induced dopamine release: Markedly blunted in cocaine dependence and predictive of the choice to self-administer cocaine. Am J Psychiatry. 2007 ; 164: 622-629
32. Minzenberg MJ, Carter CS. Modafinil: A review of neurochemical actions and effects on cognition. Neuropsychopharmacology. 2008 ; 33: 1477-1502
33. Murillo-Rodríguez E, Haro R, Palomero-Rivero M, et al. Modafinil enhances extracellular levels of dopamine in the nucleus accumbens and increases wakefulness in rats. Behav Brain Res. 2007 ; 176: 353-357
34. Nomikos GG, Damsma G, Wenkstern D, et al. In vivo characterization of locally applied dopamine uptake inhibitors by striatal microdialysis. Synapse. 1990 ; 6: 106-112
35. Paxinos G, Watson C The Rat Brain in Stereotaxic Coordinates. 1986 ) The Rat Brain in Stereotaxic Coordinates. 2nd edn. London: Academic Press. London: Academic Press ; 1986 :
36. Pennick M. Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amfetamine. Neuropsychiatr Dis Treat. 2010 ; 24: 317-327
37. Richelson E, Pfenning M. Blockade by antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes: Most antidepressants selectively block norepinephrine uptake. Eur J Pharmacol. 1984 ; 104: 277-286
38. Rowley HL, Kulkarni R, Gosden J, et al. Lisdexamfetamine and immediate release d-amfetamine - differences in pharmacokinetic/pharmacodynamic relationships revealed by striatal microdialysis in freely-moving rats with simultaneous determination of plasma drug concentrations and locomotor activity. Neuropharmacology. 2012 ; 63: 1064-1074
39. Rush CR, Essman WD, Simpson CA, et al. Reinforcing and subject-rated effects of methylphenidate and d-amphetamine in non-drug-abusing humans. J Clin Psychopharmacol. 2001 ; 21: 273-286
40. Rush CR, Kelly TH, Hays LR, et al. Discriminitive-stimulus effects of modafinil in cocaine-trained humans. Drug Alcohol Depend. 2002 ; 67: 311-322
41. Schachter HM, Pham B, King J, et al. How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents?. Can Med Assoc J. 2001 ; 165: 1475-1488
42. Sharman DF. Changes in the metabolism of 3,4-dihydroxyphenylethylamine (dopamine) in the striatum of the mouse induced by drugs. Br J Pharmacol Chemother. 1966 ; 28: 158-163
43. Sharp T, Zettetström T, Ljungberg T, et al. A direct comparison of amphetamine-induced behaviours and regional brain dopamine release in the rat using intracerebral dialysis. Brain Res. 1987 ; 401: 322-330
44. Smith RC, Davis JM. Comparative effects of d-amphetamine, l-amphetamine, and methylphenidate on mood in man. Psychopharmacology. 1977 ; 53: 1-12
45. Swanson JM, Greenhill LL, Lopez FA, et al. Modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: Results of a randomized, double-blind, placebo-controlled, fixed-dose study followed by abrupt discontinuation. J Clin Psychiat. 2006 ; 67: 137-147
46. Szporny L, Görög P. Investigations into the correlations between monoamine oxidase inhibition and other effects due to methylphenidate and its stereoisomers. Biochem Pharmacol. 1961 ; 8: 263-268
47. Volkow ND, Wang G-J, Fowler JS, et al. Reinforcing effects of psychostimulants in humans are associated with increases in brain dopamine and occupancy of D2 receptors. J Pharmacol Exp Ther. 1999 ; 291: 409-415
48. Volkow ND, Fowler JS, Logan J, et al. Effects of modafinil on dopamine and dopamine transporters in the male human brain: Clinical implications. J Am Med Assoc. 2009 ; 301: 1148-1154
49. Wigal SB, Biederman J, Swanson JM, et al. Efficacy and safety of modafinil film-coated tablets in children and adolescents with or without prior stimulant treatment for attention-deficit/hyperactivity disorder: Pooled analysis of 3 randomized, double-blind, placebo-controlled studies. Prim Care Companion J Clin Psychiatry. 2006 ; 8: 352-360
50. Wisor JP, Nishino S, Sora I, et al. Dopaminergic role in stimulant-induced wakefulness. J Neurosci. 2001 ; 21: 1787-1794
51. Zolkowska D, Jain R, Rothman RB, et al. Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil. J Pharmacol Exp Ther. 2009 ; 329: 738-746